UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): **August 13, 2025**

KIORA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

001-36672	**98-0443284**
(Commission File Number)	(IRS Employer Identification No.)

169 Saxony Rd.
Suite 212
Encinitas, CA 92024

(858) 224-9600
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:	**Trading Symbol(s)**	**Name of each exchange on which registered:**
Common Stock, $0.01 par value	KPRX	NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

Kiora Pharmaceuticals, Inc. (the "Company") hereby furnishes the updated investor presentation attached as Exhibit 99.1 to this Current Report on Form 8-K, which the Company may use in presentations to investors from time to time.

The information furnished pursuant to Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

The information furnished in this report, including Exhibit 99.1, shall not be deemed to constitute an admission that such information or exhibit is required to be furnished pursuant to Regulation FD or that such information or exhibit contains material information that is not otherwise publicly available. In addition, the Company does not assume any obligation to update such information or exhibit in the future.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Title
99.1	Company Presentation
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

*Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and Exchange Commission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

KIORA PHARMACEUTICALS, INC.

By: /s/ Melissa Tosca
Melissa Tosca
Chief Financial Officer
(Principal financial and accounting officer)

Date: August 13, 2025

Kiora Pharmaceuticals, Inc.

NASDAQ: KPRX

13 Aug 2025 | Corporate Overview

KIORA PHARMACEUTICALS

H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Forward Looking Statements

Some of the statements in this presentation are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's development-stage products, including KIO-301 and KIO-104, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all, the potential ability of KIO-301 to restore vision in patients with RP, the expecting timing of enrollment, dosing and topline results for the ABACUS study, the ability to develop KIO-301 for Choroideremia and Stargardt Disease and KIO-104 for retinal inflammatory diseases, the ability to utilize strategic relationships to develop certain product candidates, Kiora's ability to maintain the listing of our common stock on a national securities exchange, and Kiora's ability to achieve the specific milestones described herein. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this presentation, including, among other things, the ability to conduct clinical trials on a timely basis, the ability to obtain any required regulatory approvals, market and other conditions and certain risk factors described under the heading "Risk Factors" contained in Kiora's Annual Report on Form 10-K filed with the SEC on March 25, 2025, or described in Kiora's other public filings. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this presentation speak only as of the date of this presentation. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law.

Why Retinal Diseases?

"...the last light sensations faded and the dark discs had finally overwhelmed me. I had fought them bravely, as it seemed to me, for thirty-six years, but to no avail. It was then I began to sink into the deep ocean, and finally learn how to touch the rock on the far side of despair."

- John M. Hull, *Touching the Rock*



Quality of life	Falls
Independence	Injury
Mobility	Unemployment
Mental Health	Isolation

JAMA Ophthalmol. 2016;134(10)

Corporate Highlights

Developing Two Innovative Drugs	KIO-301	Molecular photoswitch has potential to restore vision lost to an IRD
	KIO-104	Anti-inflammatory, disease modifying drug for retinal inflammation
Targeting Significant Patient Need	KIO-301	100K patients in US with RP and other IRDs
	KIO-104	1.2M patients in US with key retinal inflammatory diseases
De-Risked Partnership Network with Upside on Both Programs	KIO-301	▪ Théa owns global commercial & distribution rights (outside Asia) ▪ Kiora reimbursed for R&D, milestones up to $285 MM + tiered royalties that can exceed 20% ▪ Senju option for Asian commercial & distribution rights ▪ Up to $110 MM in milestones + double digit tiered royalties
	KIO-104	Kiora controls worldwide rights

Financial Metrics & Capital Structure

Select Metrics

Cash & short-term investments	$20.7 MM
Receivables & tax credits	$3.1 MM
Runway	Late 2027
Phase 2 readouts expected	Early 2027
Market cap (inc. PFWs)	~$11 MM

Cap Structure

Common TSO	3.4 MM shares
PFWs	0.9 MM shares
Effective TSO	4.3 MM shares

Top Holders: Own ~50% of Effective TSO*

	Owner	Shares
1	AIGH Capital Management‡	259,289
2	Rosalind Advisors	250,059
3	Nantahala Capital Management	211,110
4	Stonepine Capital	200,647
5	Adar1 Capital	194,665
6	Velan Capital Investment	122,223

*Data sourced from NASDAQ, includes PFWs
‡ Includes Worth Venture Partners

As of Jun 30, 2025. PFWs – Pre-Funded Warrants, TSO – Total Shares Outstanding

Targeting the Retina to Slow, Stop, or Restore Vision Loss

Development Pipeline of Proprietary Small Molecule Therapeutics

Product	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Commercial Rights
KIO-301 Intravitreal	Retinitis Pigmentosa (Mutation Agnostic)*					Théa Open Innovation (global less Asia)
	Choroideremia					Senju Pharmaceutical holds exclusive option rights in key Asian countries
	Stargardt Disease					
KIO-104 Intravitreal	Retinal Inflammation					Kiora Pharmaceuticals
	Proliferative Vitreoretinopathy					

* - Orphan Disease Designation granted in the USA and EU

KIO-301

Small Molecule Targeting Vision Restoration

Inherited Retinal Diseases

Downstream Neurons Remain Viable



- Many Inherited Retinal Diseases, including Retinitis Pigmentosa (RP), result in death of photoreceptors
- Bipolar Cells and Retinal Ganglion Cells (RGCs) remain intact and retain ability to send signals to the brain

KIO-301 (MOA): Turns RGCs "ON" in the Presence of Light

- When photoreceptors die ⟶ downstream neurons (RGCs) are not capable of being activated
- KIO-301 preferentially enters these RGCs and turns them "ON" in the presence of light*





‡ P2X7 is solely expressed on RGCs and amacrine cells in the retina

* Visual light causes reversible isomeric shift, altering ion flux through K_V/HCN channels

Neuron. 92, 100-113 (2016)

KIO-301 Reanimates the Retina & Changes Behavior

Extensive Validation in Preclinical Models



Neuron 2014: 81, 800-813.

Retinitis Pigmentosa

A Disease with No Available Treatments

Normal Vision

Vision Declines over Time



Market Opportunity

- ~100k patients in US (Provider: Retina Specialists [~3k])
- Estimated total cost to US healthcare system in 2019: $3.7B

Clinical Presentation

- Night blindness, reduced visual field range and eventual loss of central vision
- Visual acuity declines
- 50% of patients are not qualified to drive by age 37 and legally blind by 55

Etiology

- 50+ genetically distinct subtypes from 150+ mutations
- Inherited disease

IOVS: Visual Field Progression in Retinitis Pigmentosa, AAO, Clin Ophtha 2021.:15. 2855–2866.

KIO-301: Phase 1b Study Design (ABACUS)

Open Label, Single Ascending Dose Trial – 2 Sites (Australia)



Study Design	▪ Two Cohorts, non-randomized, open-label, single IVT injection per eye ▪ Cohort 1 – NLP/BLP patients; Cohort 2 – HM/CF patients
Endpoints	▪ Primary – AEs, PK & labs ▪ Secondary – Assessment days (shown only for Cohort 1 above) is repeated for each cohort per eye; intensity & contrast assessment, kinetic perimetry, functional MRI, etc.
Review	▪ Safety review conducted by Investigators between after sentinel subject

NLP – No Light Perception, BLP – Bare Light Perception, HM – Hand Motion, CF – Counting Fingers

Changes in Vision & Patient QoL

Kinetic Visual Field

Mean Change from BL ± 80% CL



*p<0.05

Visual Acuity

Mean ± SEM



High Contrast Room Exit Test

Mean ± SEM



Quality of Life Survey



Functional MRI

Significantly Increased of Cortical Activity





NLP – No Light Perception, BLP – Bare Light Perception, CF – Counting Fingers

Patient Testimonials

www.youtube.com/@kiorapharma

KIORA PHARMACEUTICALS

CLINICAL TRIAL PATIENT TESTIMONIALS
Phase I/II KIO-301

Nasdaq: KPRX

Additional videos available at https://kiorapharma.com/inherited-retinal-diseases/

ABACUS-1 Phase 1b Clinical Trial Key Takeaways

No Safety & Tolerability Concerns

1. KIO-301 appears to reanimate the retina
   - Concordance of improvement in visual acuity, visual field & functional vision
   - Increased visual cortex activity
2. Clear pathway to approvability
   - Functional vision improvement in multiluminance testing
3. Patients report improvements in vision
   - Consistent with objective clinical assessments
   - Follow-on study will include sham group
4. Pilot study limitations
   - Non-controlled
   - Small sample size

KIO-301-2101: Phase 2 ABACUS-2

Multiple Dose, Bilateral Injection, Double-Masked, 36-Patient, Randomized, Controlled Trial



Recruitment in each Cohort begins with 6 patients (1:1) for SRC review and escalation/de-escalation recommendation

KIO-104

Intravitreal Small Molecule DHODH Inhibitor

Steroid-Sparing Approach to Retinal Inflammation

DHODH Inhibition Causes Nucleotide Starvation in Activated T-Cells





Pyrimidines are key co-factor for glycoprotein, glycolipid, and phospholipid synthesis

KIO-104: Proliferative Vitreoretinopathy

Rabbit Model of Retinal Detachment



Retinal Inflammation: Posterior Non-Infectious Uveitis

T Cell Driven Inflammation in the Back of the Eye Can Lead to Vision Loss

Need for steroid-sparing anti-inflammatory delivered locally to the eye

Major Causes

Autoimmune disorders (i.e., lupus, multiple sclerosis, psoriasis, rheumatoid arthritis, ulcerative colitis) where signs & symptoms occur in eye

Limitations of Current Treatments

Extended steroid use can lead to glaucoma & cataracts among other complications

Systemic autoimmune disease drugs can compromise immunity with minimal impact in the eye

Incidence

Estimated 400,000 in U.S. alone (121 per 100,000*)

Complications

Recurring flareups can cause vision loss and irreversible damage

* *JAMA Ophthalmol. 2016;134(11):1237-1245*

Phase 1/2a SAD Study Design

Posterior Non-Infectious Uveitis

Duration [Study Days]	-14	-7	0	2	7	14	21	28
Tasks	Screening / Baseline		KIO-104 Injection	Exam	Exam	Exam	Exam	Exam

Study Design

- Patients with chronic, posterior non-infectious uveitis
- Prospective, open label, multi-center, dose escalating, 4 patients in each Cohort, 12 patients in total

Objectives

- Safety and tolerability
- Improvement of inflammation
- Blood PK of KIO-100

KIO-104 Administration

- Single intravitreal injection of 300ng, 600ng, and 1200ng

Phase 1/2a Results: KIO-104 Improved Visual Acuity and Reduced Cystoid Macular Edema





‡ 40% of eyes with vision threatening cystoid macular edema at baseline had clinically meaningful improvement

** Historical Controls (Yeh et al, Retina 00, 1-9, 2018; Suhler et al. Visual III, Ophthalmology 125, 7, 2018.)*
IVT - Intravitreal

KIO-104: Phase 2 MAD Study Design (KLARITY)

2-Step, Randomized, Open-Label, Steroid-Sparing, Dose Expansion Trial



Study Design

- Part A: Dose informing short-term study in macular edema (multiple clinical indications)
- Part B: Dose expansion with highest tolerated dose

Endpoints

- Primary: AEs, PK, labs
- Secondary: BCVA, CST, PROs

* Indications include Diabetic Macular Edema (DME), Posterior Non-Infectious Uveitis, others

Thank You

KIORA PHARMACEUTICALS

NASDAQ: KPRX